HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The expression of vascular endothelial growth factor determines the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer.

Abstract
The aim of this study was to determine any correlation between the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines and the vascular endothelial growth factor (VEGF) expression in primary colorectal cancer tissues. The data were reviewed retrospectively on 342 patients with colorectal cancer at stage II or III, who underwent potentially curative resection between 1988 and 1998. Of these, 225 received post-operative administration of oral fluoropyrimidines such as UFT and 5'-DFUR, while the other 117 patients underwent surgery alone. Immunostaining for VEGF was performed using colorectal tumours. Overall, VEGF was positively expressed in primary tumour cells in 48% of patients. The disease-free survival rate and the overall survival rate in the chemotherapy group were higher than those in the surgery-alone group, although not significantly. However, the disease-free survival rate and the overall survival rate were similar between the two groups in patients with a tumour positive for VEGF. Multivariate analysis revealed that the VEGF expression was an independent factor for post-operative recurrence, and the VEGF expression and post-operative adjuvant chemotherapy were an independent factor for overall survival, in addition to the lymph node metastasis and the venous invasion. In conclusion, the efficacy of post-operative adjuvant chemotherapy using oral fluoropyrimidines may not be as great for patients with a tumour positive for VEGF having a greater risk of post-operative recurrence. The results support further investigation on efficacy of molecular targeting therapy for VEGF in combination with oral fluoropyrimidines as post-operative adjuvant therapy in colorectal cancer positive for VEGF.
AuthorsYutaka Ogata, Keiko Matono, Tomoaki Mizobe, Nobuya Ishibashi, Shinjiro Mori, Yoshito Akagi, Satoru Ikeda, Hiroyuki Ozasa, Hidetsugu Murakami, Kazuo Shirouzu
JournalOncology reports (Oncol Rep) Vol. 15 Issue 5 Pg. 1111-6 (May 2006) ISSN: 1021-335X [Print] Greece
PMID16596171 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Floxuridine
  • Tegafur
  • doxifluridine
Topics
  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Chemotherapy, Adjuvant
  • Colorectal Neoplasms (drug therapy, metabolism, pathology)
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • Floxuridine (administration & dosage)
  • Humans
  • Male
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local (therapy)
  • Neoplasm Staging
  • Postoperative Period
  • Retrospective Studies
  • Survival Rate
  • Tegafur (administration & dosage)
  • Vascular Endothelial Growth Factor A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD